Top Ten Equity Holdings and Exposures

Source: RNS
RNS Number : 7602C
Polar Capital Global Health Tst PLC
03 September 2024
 

3rd September 2024

 

Polar Capital Global Healthcare Trust plc (the "Company")

 

Top Ten Equity Holdings and Sector and Geographic Exposure as at 30th August 2024 full Portfolio listing as at 31st July 2024 available from company's website.

 

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 30th August 2024 the top ten equity holdings and the sector and geographic breakdown were as follows:

 

Top 10 Holdings         

%

Eli Lilly & Co

8.3%

UnitedHealth Group

7.5%

Novo Nordisk A/S

7.0%

Roche

4.6%

AbbVie

4.5%

Stryker Corp

3.6%

Sanofi

3.4%

Swedish Orphan Biovitrum

3.1%

ICON

3.1%

UCB

3.0%

Total

48.2%

 

Sector Exposure

%

Pharmaceuticals

29.2%

Biotechnology

19.9%

Healthcare Equipment

17.0%

Life Sciences Tools & Services

9.1%

Managed Healthcare

7.5%

Healthcare Supplies

5.3%

Healthcare Facilities

4.4%

Metal, Glass & Plastic Containers

2.4%

Healthcare Services

2.2%

Healthcare Technology

2.0%

Healthcare Distributors

0.9%

Cash

0.0%

Total

100.0%

 

Geographic Exposure

%

United States

48.1%

Switzerland

11.9%

Denmark

9.8%

Japan

5.9%

France

5.6%

Ireland

4.0%

Netherlands

3.9%

Sweden

3.1%

Belgium

3.0%

United Kingdom

2.4%

Germany

2.2%

Cash

0.0%

Total

100.0%

 

The monthly factsheet will usually be available on the Company's website on the 10th working day after the month end and includes a commentary by the investment manager.  www.Polarcapitalhealthcaretrust.com

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUUPUAUBUPCGAW